Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 7, 2010, Pages 564-567

  Yacobovich, Joanne ^a   Stark, Pinhas ^a   Barzilai Birenbaum, Shlomit ^a   Krause, Irit ^b   Pazgal, Idit ^a   Yaniv, Isaac ^a   Tamary, Hannah ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chelator; Deferasirox; Fanconi kidney; Iron overload; Thalassemia

Indexed keywords

DEFERASIROX; ELECTROLYTE; FERRITIN; LYSOZYME; PHOSPHORUS; POTASSIUM; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD CHEMISTRY; BLOOD PH; CASE REPORT; CHILD; COUGHING; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; ENZYMURIA; FANCONI RENOTUBULAR SYNDROME; FEMALE; FERRITIN BLOOD LEVEL; GASTROENTERITIS; GLUCOSURIA; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; IRON OVERLOAD; KIDNEY PROXIMAL TUBULE; MALE; METABOLIC ACIDOSIS; PRIORITY JOURNAL; SCHOOL CHILD; SUPPLEMENTATION; BLOOD TRANSFUSION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLIC DISORDER; MULTIMODALITY CANCER THERAPY;

ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; COMBINED MODALITY THERAPY; FANCONI SYNDROME; FEMALE; HUMANS; IRON CHELATING AGENTS; KIDNEY TUBULES, PROXIMAL; MALE; TRIAZOLES; WATER-ELECTROLYTE IMBALANCE;

EID: 77958173787     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181ec0c38     Document Type: Article

References (14)

1. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455-3462.
2. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally administered iron chelator, in comparison to deferoxamine in thalassaemia patients with transfusional iron overload. Haematologica. 2006;91:873-880.
3. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation on deferasirox, a once daily oral chelating agent, in paediatric patients with b-thalassaemia major. Haematologica. 2006;91:1343-1351.
4. Cappellini MD, Vichinsky E, Galanello R, et al. Long-term treatment with deferasirox (Exjade, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias. Blood. 2007;110:2777. [ASH Annual Meeting Abstracts].
5. Sumboonnanonda A, Malasit P, Tanphaichitr A, et al. Renal tubular function in beta-thalassemia. Pediatr Nephrol. 1998; 12:280-283.
6. Aldulak B, Karabay Bayazit A, Noyan A, et al. Renal function in pediatric patients with b-thalassemia major. Pediatr Nephrol. 2000;15:109-112.
7. Smolkin V, Halevy R, Levin C, et al. Renal function in children with b-thalassemia major and thalassemia intermedia. Pediatr Nephrol. 2008;23:1847-1851.
8. Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. In: Hershko C, ed. Iron Chelation Therapy. New York: Kluwer Academic/Plenum Publishers; 2002:185-203.
9. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/ deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin. 2008;32: 1-15.
10. Kontoghiorghes GJ. Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. Expert Opin Drug Saf. 2008;7:645-646.
11. Piga A, Vichinsky E, Forni GL, et al. Long-term efficacy and safety with deferasirox (Exjade, ICL670), a once-daily oral iron chelator, in pediatric patients. Blood. 2007;110:2774. [ASH Annual Meeting Abstracts].
12. Even-Or E, Becker-Cohen R, Miskin H. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol. 2009;85:132-134.
13. Rafat C, Fakhouri F, Ribeil J-A. Fanconi syndrome due to deferasirox. Am J Kidney Dis. 2009;54:931-934.
14. Foreman JW. Cystinosis and Fanconi syndrome. In: Avner ED, Harmon WE, Niaudet P, eds. Pediatric Nephrology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2004: 789-806.